Friday, 20 November 2026
Rīga TV

World and Latvian news in one place

HealthPublished: 20 November 2026 at 03:05

Experimental compound burns fat in mice while preserving muscle

University of California, Berkeley researchers have found a compound, TOFA, that raises energy expenditure and reduces fat rather than muscle in mice. Its safety and effectiveness in humans have not been established.

Foto: ScienceDaily Veselība

Researchers at the University of California, Berkeley, in the United States, have published a study in Science Advances on an experimental compound that helped mice lose fat without a significant loss of muscle mass. The finding may point to a new direction for treating obesity, diabetes and fatty liver disease, but so far the results come only from animal experiments.

The compound is called TOFA (5-tetradecyloxy-2-furoic acid). It was first discovered in the 1970s, but the new work identified additional properties. It belongs to the group of ACC inhibitors, which slow enzymes that help produce fatty acids. TOFA also activates two cellular receptors, PPARα and PPARδ, which regulate fat-metabolism genes and help cells take up fatty acids and break them down for energy.

Results in mice

In mice, treatment improved insulin sensitivity, lowered triglyceride levels and eased signs of fatty liver disease. Obese animals lost weight mainly through reduced body fat rather than lean muscle. Energy expenditure rose by as much as 18%, although the mice did not become more active and their body temperature did not rise. Unlike other ACC inhibitors, TOFA did not raise blood triglycerides.

When mice were given a combination of two separate compounds, one blocking lipid production and the other stimulating energy expenditure, the metabolic improvement was smaller than with TOFA alone.

Combination with GLP-1 drugs

GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound mainly reduce appetite and calorie intake, and can cause side effects including nausea and loss of muscle mass. The researchers tested TOFA alongside semaglutide and tirzepatide. The combinations produced greater effects on body weight, glucose control, insulin and triglycerides than either treatment alone.

"We view it as complementary rather than as a replacement," said Anders Näär, professor of metabolic biology and nutrition at UC Berkeley and the study's senior author.

Next steps

TOFA's safety and effectiveness in humans have not been established. To move the research toward clinical use, the scientists have founded a biotechnology company, ReRx Therapeutics.

Comments

0/1500

Comments are automatically moderated. No hate, threats, personal data or spam.

Loading comments…

More in this category